OCUGEN, INC. Form 8-K (June 12, 2020)

Summary

Current report on Form 8-K of Ocugen, Inc. with a date of earliest event reported of June 12, 2020, covering Item 1.01 and Item 9.01. It reports that on June 12, 2020 Ocugen entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. for at-the-market sales of common stock, and that a prospectus supplement filed the same day covers up to $6,160,000 of shares under a Form S-3 (File No. 333-237456). Cantor Fitzgerald receives a commission of 3.0% of the gross sales price, and the company agreed to reimburse fees and expenses of up to $15,000. The report states that 110,224,418 shares were outstanding as of June 12, 2020, and lists an opinion of Pepper Hamilton LLP as Exhibit 5.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15
(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event
Reported): June 12, 2020

OCUGEN, INC.

(Exact Name of Registrant as Specified in
its Charter)

Delaware | 001-36751 | 04-3522315
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number)

5 Great Valley Parkway, Suite 160

Malvern , Pennsylvania 19355

( 484 ) 328-4701

(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):

¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
¨ | Pre–commencement
communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
¨ | Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section
12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common
 Stock, $0.01 par value per share | OCGN | The Nasdaq Stock Market LLC (The Nasdaq Capital
 Market)

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ¨

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨

Item 1.01 Entry into a Material Definitive Agreement

On June 12, 2020, Ocugen, Inc. (the “ Company ”)
entered into a Controlled Equity Offering SM Sales Agreement (the “ Agreement ”) with Cantor Fitzgerald
 & Co. (“ Cantor Fitzgerald ”), pursuant to which the Company may, from time to time, issue and sell shares
of its common stock, par value $0.01 per share (the “ Shares ”).

Under the terms of the Agreement, Cantor
Fitzgerald may sell the Shares at market prices by any method that is deemed to be an “at the market offering”
as defined in Rule 415 promulgated under the Securities Act of 1933, as amended.

The offer and sales of the Shares made pursuant
to the Agreement, if any, will be made under the Company’s effective “shelf” registration statement on Form S-3
(File No. 333-237456), the base prospectus contained therein dated May 5, 2020, and a prospectus supplement. On June 12, 2020,
the Company filed a prospectus supplement related to the offering for up to $6,160,000 of the Shares.

This Current Report on Form 8-K shall not
constitute an offer to sell or the solicitation of any offer to buy the Shares, nor shall there be an offer, solicitation or sale
of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of such state.

The Company is not obligated to, and it
cannot provide any assurances that it will, make any sales of the Shares under the Agreement. The Agreement may be terminated by
Cantor Fitzgerald or the Company at any time upon ten days’ prior written notice to the other party. The Company will pay
Cantor Fitzgerald a commission rate of 3.0% of the gross sales price per share of any Shares sold through Cantor Fitzgerald as
sales agent under the Agreement. The Company has also provided Cantor Fitzgerald with customary indemnification and contribution
rights. The Company has agreed to reimburse Cantor Fitzgerald for its fees and expenses, including but not limited to fees and
expenses of its counsel, in an amount not to exceed $15,000.

As of June 12, 2020, 110,224,418 shares of the Company's common stock are outstanding.

The foregoing description of the Agreement
is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which was filed as
Exhibit 10.1 hereto and incorporated herein by reference.

The legal opinion of Pepper Hamilton LLP,
counsel to the Company, relating to the Shares is filed as Exhibit 5.1 hereto.

1

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No. | Document
5.1 | Opinion of Pepper Hamilton LLP
10.1 | Controlled Equity Offering SM Sales Agreement, dated June 12, 2020, by and between Ocugen, Inc. and Cantor Fitzgerald & Co.
23.1 | Consent of Pepper Hamilton LLP (included in Exhibit 5.1)
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 12, 2020

OCUGEN, INC.
By: | /s/ Shankar Musunuri
Name: Shankar Musunuri
Title: Chief Executive Officer and Chairman

3

File and source

File

SEC_OCGN_8-K_filed2020-06-12_0001104659-20-072940.htm

Size

32,794 bytes

SHA-256

514e4ceb0036168462e05cfa64738a5c0db9b9ff6dcfb394b04603ce482a86fd

Our copy

SEC_OCGN_8-K_filed2020-06-12_0001104659-20-072940.htm

Original

www.sec.gov